These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
440 related items for PubMed ID: 25179572
1. Treatment of venous thrombosis with an oral direct factor Xa inhibitor edoxaban by single and multiple administrations in rats. Morishima Y, Kamisato C, Honda Y. Eur J Pharmacol; 2014 Nov 05; 742():15-21. PubMed ID: 25179572 [Abstract] [Full Text] [Related]
2. Comparison of antithrombotic and haemorrhagic effects of edoxaban, an oral direct factor Xa inhibitor, with warfarin and enoxaparin in rats. Morishima Y, Honda Y, Kamisato C, Tsuji N, Kita A, Edo N, Shibano T. Thromb Res; 2012 Sep 05; 130(3):514-9. PubMed ID: 22647432 [Abstract] [Full Text] [Related]
3. Impact of antithrombin deficiency on efficacy of edoxaban and antithrombin-dependent anticoagulants, fondaparinux, enoxaparin, and heparin. Fukuda T, Kamisato C, Honda Y, Matsushita T, Kojima T, Furugohri T, Morishima Y, Shibano T. Thromb Res; 2013 Jun 05; 131(6):540-6. PubMed ID: 23673387 [Abstract] [Full Text] [Related]
4. Comparison of antithrombotic efficacy between edoxaban, a direct factor Xa inhibitor, and fondaparinux, an indirect factor Xa inhibitor under low and high shear rates. Fukuda T, Tsuji N, Honda Y, Kamisato C, Morishima Y, Shibano T. Thromb Haemost; 2011 Dec 05; 106(6):1062-8. PubMed ID: 21946952 [Abstract] [Full Text] [Related]
5. Prevention of arterial thrombosis by edoxaban, an oral factor Xa inhibitor in rats: monotherapy and in combination with antiplatelet agents. Honda Y, Kamisato C, Morishima Y. Eur J Pharmacol; 2016 Sep 05; 786():246-252. PubMed ID: 27288116 [Abstract] [Full Text] [Related]
6. Comparison of antithrombotic and hemorrhagic effects of edoxaban, a novel factor Xa inhibitor, with unfractionated heparin, dalteparin, lepirudin and warfarin in rats. Morishima Y, Honda Y, Kamisato C, Shibano T. Thromb Res; 2013 Aug 05; 132(2):234-9. PubMed ID: 23768448 [Abstract] [Full Text] [Related]
7. Safety and efficacy of edoxaban, an oral factor Xa inhibitor, versus enoxaparin for thromboprophylaxis after total knee arthroplasty: the STARS E-3 trial. Fuji T, Wang CJ, Fujita S, Kawai Y, Nakamura M, Kimura T, Ibusuki K, Ushida H, Abe K, Tachibana S. Thromb Res; 2014 Dec 05; 134(6):1198-204. PubMed ID: 25294589 [Abstract] [Full Text] [Related]
9. Magnetic resonance venography to assess thrombus resolution with edoxaban monotherapy versus parenteral anticoagulation/warfarin for symptomatic deep vein thrombosis: A multicenter feasibility study. Piazza G, Mani V, Goldhaber SZ, Grosso MA, Mercuri M, Lanz HJ, Schussler S, Hsu C, Chinigo A, Ritchie B, Nadar V, Cannon K, Pullman J, Concha M, Schul M, Fayad ZA, edoxaban Thrombus Reduction Imaging Study (eTRIS) Investigators. Vasc Med; 2016 Aug 05; 21(4):361-8. PubMed ID: 27165711 [Abstract] [Full Text] [Related]
10. Edoxaban: a focused review of its clinical pharmacology. Lip GY, Agnelli G. Eur Heart J; 2014 Jul 21; 35(28):1844-55. PubMed ID: 24810388 [Abstract] [Full Text] [Related]
11. Edoxaban in the prevention and treatment of thromboembolic complications from a clinical point of view. Barrios V, Escobar C. Expert Rev Cardiovasc Ther; 2015 Jul 21; 13(7):811-24. PubMed ID: 26068539 [Abstract] [Full Text] [Related]
12. Safety and efficacy of edoxaban in patients undergoing hip fracture surgery. Fuji T, Fujita S, Kawai Y, Nakamura M, Kimura T, Kiuchi Y, Abe K, Tachibana S. Thromb Res; 2014 Jun 21; 133(6):1016-22. PubMed ID: 24680549 [Abstract] [Full Text] [Related]
13. Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study. Raskob G, Cohen AT, Eriksson BI, Puskas D, Shi M, Bocanegra T, Weitz JI. Thromb Haemost; 2010 Sep 21; 104(3):642-9. PubMed ID: 20589317 [Abstract] [Full Text] [Related]
14. Comparison of a direct Factor Xa inhibitor, edoxaban, with dalteparin and ximelagatran: a randomised controlled trial in healthy elderly adults. Samama MM, Kunitada S, Oursin A, Depasse F, Heptinstall S. Thromb Res; 2010 Oct 21; 126(4):e286-93. PubMed ID: 20807664 [Abstract] [Full Text] [Related]
15. Safety and efficacy of edoxaban, an oral factor xa inhibitor, for thromboprophylaxis after total hip arthroplasty in Japan and Taiwan. Fuji T, Wang CJ, Fujita S, Kawai Y, Kimura T, Tachibana S. J Arthroplasty; 2014 Dec 21; 29(12):2439-46. PubMed ID: 25047458 [Abstract] [Full Text] [Related]
16. Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents. Fukuda T, Honda Y, Kamisato C, Morishima Y, Shibano T. Thromb Haemost; 2012 Feb 21; 107(2):253-9. PubMed ID: 22186946 [Abstract] [Full Text] [Related]
17. The Efficacy and Safety of Edoxaban for VTE Prophylaxis Post-Orthopedic Surgery: A Systematic Review. AlHajri L, Jabbari S, AlEmad H, AlMahri K, AlMahri M, AlKitbi N. J Cardiovasc Pharmacol Ther; 2017 May 21; 22(3):230-238. PubMed ID: 27811198 [Abstract] [Full Text] [Related]
18. Edoxaban: a new oral direct factor xa inhibitor. Camm AJ, Bounameaux H. Drugs; 2011 Aug 20; 71(12):1503-26. PubMed ID: 21861537 [Abstract] [Full Text] [Related]
19. Comparison of the effect of edoxaban, a direct factor Xa inhibitor, with a direct thrombin inhibitor, melagatran, and heparin on intracerebral hemorrhage induced by collagenase in rats. Shirasaki Y, Morishima Y, Shibano T. Thromb Res; 2014 Apr 20; 133(4):622-8. PubMed ID: 23932349 [Abstract] [Full Text] [Related]
20. Edoxaban administration following enoxaparin: a pharmacodynamic, pharmacokinetic, and tolerability assessment in human subjects. Zahir H, Matsushima N, Halim AB, He L, Zhang G, Lee F, Worland V, Mendell J. Thromb Haemost; 2012 Jul 20; 108(1):166-75. PubMed ID: 22628060 [Abstract] [Full Text] [Related] Page: [Next] [New Search]